Napo Pharmaceuticals, a Jaguar Health (NASDAQ: JAGX) (“Jaguar”) company, focuses on developing and commercializing proprietary human pharmaceuticals from plants harvested responsibly from rainforest areas. Jaguar is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar is the majority shareholder of Napo Therapeutics S.p.A., a corporation established by Jaguar in Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, focuses on developing novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults. For more information about Napo Pharmaceuticals, please visit www.napopharma.com. For more information about Jaguar, visit https://jaguar.health. For more information about Napo Therapeutics, visit napotherapeutics.com. For more information about Magdalena Biosciences, visit magdalenabiosciences.com. To read our full social media policy, please visit https://jaguar.health/social-media-policy